This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

Summary

The purpose of this study is to establish the maximum tolerated dose (MTD) of OBI-888 as monotherapy. And to characterize the safety and preliminary clinical activity profile of the MTD dose of OBI-888 administered as monotherapy in patients with locally advanced or metastatic solid tumors.

Timeline

Start

2018-05-07

Primary completion

2022-04-07

Completion

2022-04-07

Outcome

Outcome not reported

Stopped: “OBI-888 no longer fulfills our goal of developing cost-effective therapies for cancer patients”

Drugs

Indications